Rare Cancer News & Clinical Trials » Google - Neuroendocrine Tumor

Feeds

4304 items (4304 unread) in 80 feeds

• Google - Acinar Cell Carcinoma (5 unread)
• PubMed - Acinar Cell Carcinoma (23 unread)
• Trial - Acinar Cell Carcinoma

• Google - Acinic Cell Carcinoma (5 unread)
• PubMed - Acinic Cell Carcinoma (27 unread)
• Trial - Acinic Cell Carcinoma

• Google - Adenoid Cystic Carcinoma (15 unread)
• PubMed - Adenoid Cystic Carcinoma (33 unread)
• Trial - Adenoid Cystic Carcinoma (4 unread)

• Google - Adrenal Cancer (86 unread)
• Google - Adrenocortical Carcinoma (16 unread)
• PubMed - Adrenal Cancer (161 unread)
• PubMed - Adrenocortical Carcinoma (30 unread)
• Trial - Adrenal Cancer (8 unread)
• Trial - Adrenocortical Carcinoma

• Google - Ampullary Cancer (1 unread)
• PubMed - Ampullary Cancer (12 unread)
• Trial - Ampullary Carcinoma

• Google - Anal Cancer (148 unread)
• PubMed - Anal Cancer (92 unread)
• Trial - Anal Cancers (9 unread)

• Google - Angiosarcoma (20 unread)
• PubMed - Angiosarcoma (45 unread)
• Trial - Angiosarcoma (2 unread)

• Google - Appendix Cancer (6 unread)
• PubMed - Appendix Cancer (20 unread)
• Trial - Appendix Cancer (7 unread)

• Google - Bile Duct Cancer (74 unread)
• Google - Cholangiocarcinoma (29 unread)
• PubMed - Bile Duct Cancer (152 unread)
• PubMed - Cholangiocarcinoma (99 unread)
• Trial - Bile Duct Cancer (6 unread)
• Trial - Cholangiocarcinoma (11 unread)

• Google - Rare Brain Tumor (518 unread)
• Google - Rare CNS Tumor (1 unread)
• PubMed - Ganglioglioma (7 unread)
• PubMed - Rare Brain Tumor (101 unread)
• PubMed - Rare CNS Tumor (116 unread)
• Trial - Brain Tumor (129 unread)
• Trial - CNS Tumor (189 unread)
• Trial - Ganglioglioma

• Google - Carcinoid (52 unread)
• PubMed - Carcinoid (79 unread)
• Trials - Carcinoid (5 unread)

• Google - Merkel Cell Cancer (39 unread)
• Google - Neuroendocrine Tumor (47 unread)
• PubMed - Merkel Cell Cancer (26 unread)
• PubMed - Neuroendocrine Tumor (91 unread)
• Trial - Merkel Cell Cancer
• Trial - Neuroendocrine Cancers (67 unread)

• Google - Gall Bladder Cancer (142 unread)
• PubMed - Gall Bladder Cancer (69 unread)
• Trials - Gall Bladder Cancer

• Google - Hemangioendothelioma
• PubMed - Hemangioendothelioma (23 unread)
• Trial - Hemangioendothelioma

• Google - Hepatoblastoma (10 unread)
• PubMed - Hepatoblastoma (20 unread)
• Trial - Hepatoblastoma

• Google - Insulinoma (4 unread)
• PubMed - Insulinoma (36 unread)
• Trial - Insulinoma (1 unread)

• Google - Phyllodes Tumor
• PubMed - Phyllodes Tumor (17 unread)
• Trial - Phyllodes

• Google - Pseudomyxoma Peritonei (6 unread)
• PubMed - Pseudomyxoma Peritonei (PMP) (10 unread)
• Trial - Pseudomyxoma Peritonei

• Google - Rhabdomyosarcoma (100 unread)
• PubMed - Rhabdomyosarcoma (65 unread)
• Trial - Rhabdomyosarcoma (8 unread)

• Google - Sarcoma (165 unread)
• PubMed - Sarcoma (313 unread)
• Trial - Sarcoma (59 unread)

• Twitter / Bruce_S (223 unread)
• Twitter / childrenscancer (235 unread)
• Twitter / LiftUpEllie (12 unread)
• Twitter / LivingBeyond (55 unread)
• Twitter / MDAndersonNews (118 unread)
• Twitter / vaginal_cancer

Google - Neuroendocrine Tumor (47 unread)

• 

  Struma ovarii with follicular thyroid-type carcinoma and neuroendocrine ... - 7thSpace Interactive (press release)

  Posted: May 21st, 2012, 6:05am MDT

  Struma ovarii with follicular thyroid-type carcinoma and neuroendocrine ... 7thSpace Interactive (press release) A 50-year-old female was subjected to upper gut endoscopy which showed a 30-mm masslocated in the gastric antrum, suggestive of mesenchimal tumor. Incidentally, a pelvic CTscan also documented a solid mass in the right adnexa, with morphological ...

• 

  Candye Kane's Cancer Surgery Successful, but... - San Diego Reader (blog)

  Posted: May 18th, 2012, 12:32am MDT

  Candye Kane's Cancer Surgery Successful, but... San Diego Reader (blog) But music is my life and neuroendocrine cancer is a mostly manageable disease. I will continue to work as much as I can because I know life is fragile anyway. I would be fine if I died onstage doing what I love like Country Dick Montana or Johnny ...

• 

  This Week in the Journal of the National Cancer Institute - GenomeWeb

  Posted: May 17th, 2012, 10:09am MDT

  This Week in the Journal of the National Cancer Institute GenomeWeb Also in the Journal of the National Cancer Institute this week, researchers in Italy examine the best way to devise a TNM — tumor, node, metastasis — staging system for pancreatic neuroendocrine neoplasms. Both the European Neuroendocrine Tumor ...

• 

  New Data from Silence's Atu027 Anticancer Trial Published at ASCO - Sacramento Bee

  Posted: May 17th, 2012, 4:59am MDT

  New Data from Silence's Atu027 Anticancer Trial Published at ASCO Sacramento Bee Two patients with neuroendocrine cancers had disease stabilisation for nine and 12 months respectively, including partial regression of liver metastases in one patient. Another patient with breast cancer demonstrated regression of liver metastases. and more »

• 

  New Data from Silence's Atu027 Anticancer Trial Published at ASCO - MarketWatch (press release)

  Posted: May 17th, 2012, 10:02pm MDT

  New Data from Silence's Atu027 Anticancer Trial Published at ASCO MarketWatch (press release) Two patients with neuroendocrine cancers had disease stabilisation for nine and 12 months respectively, including partial regression of liver metastases in one patient. Another patient with breast cancer demonstrated regression of liver metastases. and more »

• 

  New Data from Silence's Atu027 Anticancer Trial Published at ASCO - PR Newswire (press release)

  Posted: May 17th, 2012, 10:01pm MDT

  New Data from Silence's Atu027 Anticancer Trial Published at ASCO PR Newswire (press release) Two patients with neuroendocrine cancers had disease stabilisation for nine and 12 months respectively, including partial regression of liver metastases in one patient. Another patient with breast cancer demonstrated regression of liver metastases. and more »

• 

  Disappointing Data on Pfizer Drug - Zacks.com

  Posted: May 16th, 2012, 12:17pm MDT

  Disappointing Data on Pfizer Drug Zacks.com Sutent is also approved for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. Torisel is currently approved in the US and other countries for ... and more »

• 

  Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market ... - MarketWatch (press release)

  Posted: May 15th, 2012, 4:48am MDT

  Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market ... MarketWatch (press release) Summary GlobalData, the industry analysis specialist, has released its new report, "Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019". The report is an essential source of information and analysis on the global ... and more »

• 

  Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market ... - SBWire (press release)

  Posted: May 14th, 2012, 12:57pm MDT

  Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market ... SBWire (press release) Naperville, IL -- (SBWIRE) -- 05/14/2012 -- Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 report is an essential source of information and analysis on the global neuroendocrine carcinoma market. and more »

• 

  Locating Rare Pancreatic Tumors With New Imaging Technique - Medical News Today

  Posted: May 9th, 2012, 9:05am MDT

  Locating Rare Pancreatic Tumors With New Imaging Technique Medical News Today Insulinomas are pancreatic tumors derived from beta cells. They are known as secreting neuroendocrine tumors (NET) as they secrete insulin. However, they secrete insulin in an unregulated way, causing blood sugar levels to drop lower than normal. and more »

• 

  6 Best Biotech Stocks With More Upside Potential - Seeking Alpha

  Posted: May 7th, 2012, 7:30am MDT

  6 Best Biotech Stocks With More Upside Potential Seeking Alpha The "410 trial" is a Phase 1/2 trial in combination with sunitinib in patients with renal cell carcinoma, gastrointestinal stromal tumors or pancreatic neuroendocrine tumors. To date, across all clinical trials, TH-302 has been administered to more ...

• 

  Novartis drug pasireotide LAR shows superior efficacy compared to SandostatinR ... - Reuters

  Posted: May 7th, 2012, 10:01pm MDT

  Novartis drug pasireotide LAR shows superior efficacy compared to SandostatinR ... Reuters Treatment of patients with advanced neuroendocrine tumors of the midgut or unknown primary tumor location. Sandostatin LAR was first approved in France in June 1995 and is currently approved in 95 countries. For more than a decade, Sandostatin LAR has ... Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin ...The FINANCIAL all 23 news articles »

• 

  It's the season for Relay for Life in the San Jose area - San Jose Mercury News

  Posted: May 3rd, 2012, 7:07pm MDT

  It's the season for Relay for Life in the San Jose area San Jose Mercury News Young is battling a neuroendocrine tumor in his chest. As winter turns to spring, work on the annual San Jose Relays For Life begins in earnest. This year, three of them--Cambrian, Almaden and Willow Glen--are within a 30 day period. and more »

• 

  Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript - Seeking Alpha

  Posted: May 3rd, 2012, 6:45pm MDT

  Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript Seeking Alpha Ongoing non-CRPC ISTs include a phase 2 trial in women with hormone receptive positive metastatic breast cancer and bone metastases, and a trial in patients with advanced Pancreatic Neuroendocrine and Carcinoid Tumors. Additional phase 1 ISPs in ... and more »

• 

  Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational ... - MarketWatch (press release)

  Posted: May 3rd, 2012, 12:31pm MDT

  Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational ... MarketWatch (press release) The "410 trial" is a Phase 1/2 trial in combination with sunitinib in patients with renal cell carcinoma, gastrointestinal stromal tumors or pancreatic neuroendocrine tumors. To date, across all clinical trials, TH-302 has been administered to more ... and more »

• 

  Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational ... - MarketWatch (press release)

  Posted: May 3rd, 2012, 12:29pm MDT

  Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational ... MarketWatch (press release) The "410 trial" is a Phase 1/2 trial in combination with sunitinib in patients with renal cell carcinoma, gastrointestinal stromal tumors or pancreatic neuroendocrine tumors. To date, across all clinical trials, TH-302 has been administered to more ... and more »

• 

  Wednesday's Bio Pharma Drug Approval And Catalyst Watch List - Seeking Alpha

  Posted: May 2nd, 2012, 3:59am MDT

  Wednesday's Bio Pharma Drug Approval And Catalyst Watch List Seeking Alpha Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract and is characterized by severe diarrhea and flushing episodes with long-term consequences that may include cardiac valve ... and more »

• 

  Afinitor for Non-Cancerous Kidney Tumors - dailyRx

  Posted: April 28th, 2012, 11:21pm MDT

  Afinitor for Non-Cancerous Kidney Tumors dailyRx The US Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex (TSC). FDA Expands Everolimus LabelMedPage Today Novartis drug AfinitorR approved by FDA as first medication to treat patients ...Reuters Novartis drug Afinitor® approved by FDA as first medication to treat patients ...PR Newswire (press release) Medscape -Genetic Engineering News all 56 news articles »

• 

  FDA Expands Everolimus Label - MedPage Today

  Posted: April 27th, 2012, 9:05am MDT

  FDA Expands Everolimus Label MedPage Today The drug also is approved to treat renal cell carcinoma that has been treated unsuccessfully with other medications, and progressive neuroendocrine tumors in the pancreas that cannot be removed by surgery or that have spread to other areas of the body. Afinitor Approved for Non-cancerous Kidney TumorsKansas City infoZine FDA accelerates approval for tuberous sclerosis drugMedCity News all 11 news articles »

• 

  Novartis' Afinitor Gets FDA Okay for Treating Renal Angiomyolipoma Associated ... - Genetic Engineering News

  Posted: April 27th, 2012, 5:54am MDT

  Novartis' Afinitor Gets FDA Okay for Treating Renal Angiomyolipoma Associated ... Genetic Engineering News Afinitor has previously been approved in the US and other markets for the treatment of adult patients with advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin, and for treating adult adn pediatric patients with ...

• 

  Afinitor Approved for Non-cancerous Kidney Tumors - Kansas City infoZine

  Posted: April 27th, 2012, 5:14am MDT

  Afinitor Approved for Non-cancerous Kidney Tumors Kansas City infoZine Washington, DC - infoZine - The US Food and Drug Administration today approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with ... FDA accelerates approval for tuberous sclerosis drugMedCity News all 3 news articles »

• 

  The Coalition to Cure Prostate Cancer Breaks Ground, Announces Four Young ... - PharmiWeb.com (press release)

  Posted: April 27th, 2012, 11:13pm MDT

  The Coalition to Cure Prostate Cancer Breaks Ground, Announces Four Young ... PharmiWeb.com (press release) The first four CCPC Young Investigators are: Neuroendocrine prostate cancer (NEPC) is a very aggressive, lethal subtype of advanced prostate cancer that is poorly understood, partly due to the lack of a good animal model in which study the disease.

• 

  Novartis drug AfinitorR approved by FDA as first medication to treat patients ... - Reuters

  Posted: April 26th, 2012, 2:01pm MDT

  Novartis drug AfinitorR approved by FDA as first medication to treat patients ... Reuters Afinitor is approved for the treatment of locally advanced, metastatic or unresectable progressive neuroendocrine tumors of pancreatic origin in adults in the US and EU. Everolimus is also available from Novartis for use in other non-oncology patient ... Novartis drug Afinitor® approved by FDA as first medication to treat patients ...PR Newswire (press release) Afinitor for Non-Cancerous Kidney TumorsdailyRx FDA Approves Everolimus for Renal AngiomyolipomasMedscape all 56 news articles »

• 

  FDA approves Afinitor for non-cancerous kidney tumors caused by rare genetic ... - FDA.gov

  Posted: April 26th, 2012, 12:39pm MDT

  FDA approves Afinitor for non-cancerous kidney tumors caused by rare genetic ... FDA.gov The US Food and Drug Administration today approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex ... FDA Expands Everolimus LabelMedPage Today FDA accelerates approval for tuberous sclerosis drugMedCity News all 10 news articles »

• 

  Now on ScienceBlogs: Stanislaw Burzynski: Kind-hearted strangers and a failure ... - ScienceBlogs (blog)

  Posted: April 25th, 2012, 11:12pm MDT

  Now on ScienceBlogs: Stanislaw Burzynski: Kind-hearted strangers and a failure ... ScienceBlogs (blog) ... her story sounds an awful lot like Steve Jobs in that she had a pancreatic tumor resected, states that she is now receiving "hormone injections" to keep her symptoms at bay (which implies to me that she had a pancreatic neuroendocrine tumor), ...

• 

  Hypothyroidism Risks With MKIs Examined - OncLive

  Posted: April 23rd, 2012, 1:42pm MDT

  OncLive

  Hypothyroidism Risks With MKIs Examined OncLive Sunitinib (Sutent) also is approved to treat certain gastrointestinal stromal tumors (GISTs) and pancreatic neuroendocrine tumors while sorafenib (Nexavar) is additionally indicated for hepatocellular carcinoma. A number of phase II trials are under ...

• 

  Osakis woman battles rare form of cancer - Alexandria Echo Press

  Posted: April 17th, 2012, 9:17pm MDT

  Osakis woman battles rare form of cancer Alexandria Echo Press After coping with bouts of abdominal pain for about five years, Dayni Imdieke was diagnosed last September with cancer, specifically, a neuroendocrine tumor on her pancreas. Two years ago, Dayni decided to have her gallbladder taken out. and more »

• 

  Study Supports Combining c-MET Targeted Therapies With Angiogenesis Inhibitors - OncLive

  Posted: April 16th, 2012, 2:22pm MDT

  OncLive

  Study Supports Combining c-MET Targeted Therapies With Angiogenesis Inhibitors OncLive Donald M. McDonald, MD, PhD, led a research group at the University of California, San Francisco, that explored single VEGF and dual inhibition strategies in preclinical mouse models of neuroendocrine pancreatic tumors. Their results confirmed that ...

• 

  Plant A Sunflower And Harvest Life - Patch.com

  Posted: April 14th, 2012, 2:00pm MDT

  Plant A Sunflower And Harvest Life Patch.com The sunflower symbol reminds us of the many individuals who dedicate themselves to discovering a cure for neuroendocrine tumors. Together we are powerful." I discovered how powerful and supportive groups like CFCF can be after I started my recovery ...

• 

  PGx Highlights from the American Association for Cancer Research Meeting - GenomeWeb

  Posted: April 13th, 2012, 6:23am MDT

  PGx Highlights from the American Association for Cancer Research Meeting GenomeWeb The researchers looked at 21 prostate cancer samples, 18 neuroendocrine prostate cancer samples, and 18 benign prostate samples. They identified 133 mutations in 30 genes, with 87 percent of cancer samples containing at least one mutation. and more »

• 

  Heart risks of cancer drugs underestimated - Oncology Nurse Advisor

  Posted: April 12th, 2012, 3:10am MDT

  Heart risks of cancer drugs underestimated Oncology Nurse Advisor Used in the treatment of renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors, sunitinib is associated with cardiac toxicity. However, the FDA labeling for the drug warned of a much higher incidence of such ...

• 

  Novel Cancer Treatment Gains Acceptance - Seeking Alpha

  Posted: April 11th, 2012, 7:27am MDT

  Novel Cancer Treatment Gains Acceptance Seeking Alpha We concluded a multi-arm Phase II trial to evaluate the Delcath CHEMOSAT system for the treatment of other cancers in the liver, such as tumors of neuroendocrine and colorectal adenocarcinoma and cholangiocarcinoma origin that have spread to the liver ... and more »

• 

  Plant A Sunflower And Harvest Life - Patch.com

  Posted: April 9th, 2012, 12:38pm MDT

  Plant A Sunflower And Harvest Life Patch.com The sunflower symbol reminds us of the many individuals who dedicate themselves to discovering a cure for neuroendocrine tumors. Together we are powerful." I discovered how powerful and supportive groups like CFCF can be after I started my recovery ...

• 

  NYU Langone Medical Center Expands Gastrointestinal Malignancies Team - Newswise (press release)

  Posted: April 6th, 2012, 11:49am MDT

  NYU Langone Medical Center Expands Gastrointestinal Malignancies Team Newswise (press release) They will specialize in gastrointestinal cancers that include: esophageal, gastric, pancreatic, liver, bile duct, carcinoid or neuroendocrine tumors of the small bowel, colon cancer, rectal cancer and cancer of the anal canal. They will have offices at ... and more »

• 

  Neuroendocrine Tumor Program Recognized for Excellence - Newswise (press release)

  Posted: April 6th, 2012, 11:49am MDT

  Neuroendocrine Tumor Program Recognized for Excellence Newswise (press release) The three are longtime collaborators on research of targeted cancer therapies. The 2012 Caring for Carcinoid Foundation-AARC grant is being awarded in recognition of their research titled “Octreotide-targeted treatment of neuroendocrine tumors of the ...

• 

  Prognostic Factors for Progression of Neuroendocrine Tumors Identified in ... - OncLive

  Posted: April 5th, 2012, 6:00am MDT

  OncLive

  Prognostic Factors for Progression of Neuroendocrine Tumors Identified in ... OncLive The placebo-controlled phase III RADIANT-2 trial showed that the addition of everolimus to standard octreotide LAR achieved about a 5-month improvement in progression-free survival (PFS) in patients with advanced neuroendocrine tumors (NETs).

• 

  Firefighters support peer in cancer battle - Seacoastonline.com

  Posted: April 5th, 2012, 10:42pm MDT

  Firefighters support peer in cancer battle Seacoastonline.com Firefighter Jeff Bokum, a 9½-year veteran of the Fire Department, was diagnosed in late November 2011 with neuroendocrine cancer, a rare cancer that is affecting his liver and thyroid. He is undergoing treatment in Houston, Texas, at MD Anderson Center ...

• 

  Relapse-free survival now easier to predict for several tumor stages - News-Medical.net

  Posted: April 4th, 2012, 5:34am MDT

  Relapse-free survival now easier to predict for several tumor stages News-Medical.net Researchers at Moffitt Cancer Center have carried out a study to validate the utility of new tumor classification systems for staging and predicting relapse-free survival for patients with neuroendocrine tumors (NETs) and who may be candidates for ...

• 

  Researchers validate staging classifications for neuroendocrine pancreatic ... - Medical Xpress

  Posted: April 3rd, 2012, 7:16am MDT

  Researchers validate staging classifications for neuroendocrine pancreatic ... Medical Xpress Researchers at Moffitt Cancer Center have carried out a study to validate the utility of new tumor classification systems for staging and predicting relapse-free survival for patients with neuroendocrine tumors (NETs) and who may be candidates for ... and more »

• 

  Researchers Validate New Staging Classifications for Neuroendocrine Pancreatic ... - Newswise (press release)

  Posted: April 3rd, 2012, 5:38am MDT

  Researchers Validate New Staging Classifications for Neuroendocrine Pancreatic ... Newswise (press release) (April 3, 2012) – Researchers at Moffitt Cancer Center have carried out a study to validate the utility of new tumor classification systems for staging and predicting relapse-free survival for patients with neuroendocrine tumors (NETs) and who may be ... and more »

• 

  1st Balkan Congress of Nuclear Medicine to be held in Antalya - Today's Zaman

  Posted: April 2nd, 2012, 6:03am MDT

  1st Balkan Congress of Nuclear Medicine to be held in Antalya Today's Zaman The main topics of the congress will be hybrid imaging, the future of nuclear cardiology, current trends in infection imaging, molecular imaging of low FDG avid tumor tissue, imaging of neuroendocrine tumors, radionuclide therapy of neuroendocrine ...

• 

  The dark side of mast cell-targeted therapy in prostate cancer - Abstract - UroToday

  Posted: March 29th, 2012, 11:14pm MDT

  The dark side of mast cell-targeted therapy in prostate cancer - Abstract UroToday The common expression of c-Kit by mast cells and neuroendocrine clones suggests a possible competition for the ligand Stem cell factor and offers the chance of curing early-stage disease while preventing neuroendocrine tumors using c-Kit-targeted ...

• 

  Prognostic Factors Elucidated in Pancreatic Neuroendocrine Tumors - Clinical Oncology News

  Posted: March 27th, 2012, 1:27pm MDT

  Clinical Oncology News

  Prognostic Factors Elucidated in Pancreatic Neuroendocrine Tumors Clinical Oncology News A team of researchers from Verona, Italy, believes it has identified two “powerful” predictors of recurrence in patients with malignant pancreatic neuroendocrine tumors (pNETs). In a study published online by the European Journal of Cancer (2011 Nov 28 ...

• 

  Radionuclide therapy may be linked to hematologic consequences in ... - HemOncToday

  Posted: March 27th, 2012, 10:05am MDT

  Radionuclide therapy may be linked to hematologic consequences in ... HemOncToday Patients with neuroendocrine tumors who have undergone iodine-131–metaiodobenzylguanidine therapy experience respectable rates of survival, but a minority develops hematological pathologies in long-term follow-up, according to research presented at the ... and more »

• 

  Radionuclide therapy may be linked to hematologic consequences in ... - Endocrine Today

  Posted: March 27th, 2012, 10:00am MDT

  Radionuclide therapy may be linked to hematologic consequences in ... Endocrine Today Patients with neuroendocrine tumors who have undergone iodine-131–metaiodobenzylguanidine therapy experience respectable rates of survival, but a minority develops hematological pathologies in long-term follow-up, according to research presented at the ... and more »

• 

  Relay for Life teams raising funds for annual main events - WatertownDailyTimes.com

  Posted: March 26th, 2012, 1:05am MDT

  Relay for Life teams raising funds for annual main events WatertownDailyTimes.com Teammate Mary S. Paradise, who has carcinoid,, or neuroendocrine, cancerous tumors, said the team holds can-and-bottle drives, garage sales, partners with local stores, hosts trips and other events to raise as much money as they can for the American ... and more »

• 

  Dr. K: New medications treat pancreatic cancer - GoErie.com

  Posted: March 23rd, 2012, 8:05pm MDT

  Dr. K: New medications treat pancreatic cancer GoErie.com Q I am a 55-year-old man who was recently diagnosed with pancreatic cancer. It is a neuroendocrine tumor. My doctor will be performing surgery in a couple of weeks and has discussed some new drugs that the FDA recently approved.

TOP Gregarius 0.6.1 Website: Rare-Cancer.org Last Update: Mon 21 May 2012 11:00:58 PM MDT